NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)

This review article provides an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long‐term follow‐up strategies for patients at risk of experiencing cancer therapy‐related cardiotoxicities

This position statement reviews the use of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging, and computed tomography in the management of cancer patients based on current evidence for the value of modern cardiovascular imaging in the cardio‐oncology field, and discusses future directions and ongoing cardiovascular imaging research.

This position statement presents evidence‐based risk stratification tools for oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities.

The most recent update to the NCCN Survivorship guidelines has added a new algorithm for cardiovascular disease risk assessment among cancer survivors, which includes the ABCDEs to Promote Cardiovascular Wellness (SCVD-1 and SCVD-1).

This review article explores the links between cancer, cancer treatment, and cardiovascular risk, including mechanisms associated with cardiotoxicity, screening and surveillance for patients undergoing cancer treatment, and effective preventative and management strategies used to reduce the incidence of cardiotoxicities in patients receiving chemotherapeutics or radiation.

This curated resource from the American College of Cardiology offers links to cardio-oncology news and JACC journal articles, education and meeting opportunities, and tools and practice support for clinicians.

Through this webpage, the International Cardio-Oncology Society provides myriad resources to help both clinicians and patients stay aware and informed about the latest in cardio-oncology.

This patient resource provides helpful information on adverse events associated with CAR T-cell therapy, including cytokine release syndrome–related atrial fibrillation, ventricular tachycardia, and decrease heart performance.

This Viewpoint article highlights the importance of reconsidering certain clinical visits, including imaging tests, for patients with cancer and/or cardiovascular disease during the ongoing COVID-19 pandemic. The authors also provide general guidance, based on available evidence, regarding the role of routine cardiac surveillance as the novel coronavirus continues to be a threat.

Developed by an American Society of Clinical Oncology expert panel and based on a systematic review of literature, these guidelines equip health care providers to discuss potential cardiac dysfunction with patients at high risk and initiate appropriate prevention and screening measures prior to beginning therapy.

Read about and listen to nationally recognized expert Elizabeth Shpall, MD, of the University of Texas MD Anderson Cancer Center, as she details best practices for managing cytokine release syndrome among patients receiving CAR T-cell therapy.

Check out this primer in cardio-oncology for a summary of the current understanding of cardiovascular toxicities associated with CD19-specific CAR T-cell therapies, proposed cardiac surveillance protocol for patients receiving the therapy, and discussion of what’s on the horizon for cardio-oncology research in this area.

Stay up to date about emerging research on the cardiotoxicities seen with many types of cancer therapy. Learn about why these cardiac effects occur, and how to best monitor for and manage them in your patients. 

Learn about the development and implementation of a cardio-oncology program in a suburban community cardiology practice, created to provide service in this area to breast cancer patients at risk for cardiotoxicity, including the use of the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework to guide the project and enhance the translation of research into practice through planning and execution.

This review explores current data on risk factors, diagnoses, and treatment options that impact cardio-oncologic patients with COVID-19, in addition to offering strategies for the treatment and management of this population.

The patient section of the Canadian Cardiac Oncology Network’s site offers patients access to information about cardiac oncology, including educational resources, clinical trials, and research articles, in addition to a frequently asked questions list and Canadian-specific clinic search.

This resource provides a click-through and searchable listing of cancer drugs, their drug class and cancer indications, and their associated cardio-toxicities, to help clinicians stay informed when treating their patients.

Learn about the etiology, mechanism, and clinical management of cytokine release syndrome—a side effect associated with novel immunotherapeutics such as CAR T-cell and bispecific T-cell engager therapies—on the cardiovascular and other organ systems, as well as grading and treatment modalities. The aim is to maximize the benefit of CAR T-cell therapy while mitigating the risk of cardiac complications.

Get up to speed on CAR T-cell therapy: how it works, which patients are candidates, what side effects to be on alert for, and what your institution needs to do to prepare to offer this revolutionary therapy.

Recognize the signs/symptoms and understand the risk factors that may be associated with the development of CAR T-cell therapy–associated cytokine release syndrome (CRS), including its cardiovascular impact, as well as the incidence, severity, and timing of CRS with different CAR T-cell products to enable earlier recognition and treatment, and therefore improvement of outcomes in patients receiving this novel therapy.